Meta-analysis: Erythropoiesis-stimulating agents in patients with chronic kidney disease

Annals of Internal Medicine

Volumn 153, Issue 1, 2010, Pages 23-33

  Palmer, Suetonia C ^a   Navaneethan, Sankar D ^b   Craig, Jonathan C ^c   Johnson, David W ^d   Tonelli, Marcello ^e   Garg, Amit X ^f   Pellegrini, Fabio ^g   Ravani, Pietro ^h   Jardine, Meg ⁱ   Perkovic, Vlado ⁱ   Graziano, Giusi ^g   McGee, Richard ^c   Nicolucci, Antonio ^g   Tognoni, Gianni ^g   Strippoli, Giovanni F M ^g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g Diaverum Medical Scientific Office ^*  (Italy)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ GEORGE INSTITUTE FOR INTERNATIONAL HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; HEMOGLOBIN;

ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; EMBASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; STROKE; SYSTEMATIC REVIEW; THROMBOSIS; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; METABOLISM; REVIEW; RISK FACTOR; TREATMENT OUTCOME; VEIN THROMBOSIS;

ANEMIA; CARDIOVASCULAR DISEASES; HEMATINICS; HEMOGLOBINS; HUMANS; HYPERTENSION; QUALITY OF LIFE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; STROKE; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 77955722809     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-153-1-201007060-00252     Document Type: Article

References (50)

1. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2002;13:504-10. [PMID: 11805181]
2. McGonigle RJ, Wallin JD, Shadduck RK, Fisher JW. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int. 1984;25:437-44. [PMID: 6727139]
3. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet. 1986;2:1175-8. [PMID: 2877323]
4. Zins B, Drüeke T, Zingraff J, Bererhi L, Kreis H, Naret C, et al. Erythropoietin treatment in anaemic patients on haemodialysis [Letter]. Lancet. 1986;2:1329. [PMID: 2878188] (Pubitemid 17177875)
5. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987;316:73-8. [PMID: 3537801]
6. Bommer J, Alexiou C, Müller-Bühl U, Eifert J, Ritz E. Recombinant human erythropoietin therapy in haemodialysis patients - dose determination and clinical experience. Nephrol Dial Transplant. 1987;2:238-42. [PMID: 3118264] (Pubitemid 18004811)
7. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ. 1990;300:573-8. [PMID: 2108751]
8. Bahlmann J, Schöter KH, Scigalla P, Gurland HJ, Hilfenhaus M, Koch KM, et al. Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study. Contrib Nephrol. 1991;88:90-106. [PMID: 2040200]
9. Clyne N, Jogestrand T. Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron. 1992;60:390-6. [PMID: 1584314]
10. Kleinman KS, Schweitzer SU, Perdue ST, Bleifer KH, Abels RI. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial. Am J Kidney Dis. 1989;14:486-95. [PMID: 2688405]
11. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77:176-85. [PMID: 9346384] (Pubitemid 27440408)
12. Morris KP, Skinner JR, Hunter S, Coulthard MG. Short term correction of anaemia with recombinant human erythropoietin and reduction of cardiac output in end stage renal failure. Arch Dis Child. 1993;68:644-8. [PMID: 8323333] (Pubitemid 23153247)
13. Nissenson AR, Korbet S, Faber M, Burkart J, Gentile D, Hamburger R, et al. Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol. 1995;5:1517-29. [PMID: 7703390]
14. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis. 1995;25:548-54. [PMID: 7702049]
15. Sikole A, Polenakovic M, Spirovska V, Polenakovic B, Masin G. Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs. 1993;17:977-84. [PMID: 8110072] (Pubitemid 24025978)
16. Watson AJ, Gimenez LF, Cotton S, Walser M, Spivak JL. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. Am J Med. 1990;89:432-5. [PMID: 2220877] (Pubitemid 20365390)
17. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369:381-8. [PMID: 17276778] (Pubitemid 46188479)
18. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-32. [PMID: 19880844]
19. Strippoli GF, Navaneethan SD, Craig JC. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2006:CD003967. [PMID: 17054191]
20. Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2. The Cochrane Collaboration; 2009.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. [PMID: 12958120]
22. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-90. [PMID: 9718377] (Pubitemid 28385655)
23. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-98. [PMID: 17108343]
24. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005;16:2180-9. [PMID: 15901766] (Pubitemid 41716451)
25. Berns JS, Rudnick MR, Cohen RM, Bower JD, Wood BC. Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. Kidney Int. 1999;56:253-60. [PMID: 10411700]
26. Brandt JR, Avner ED, Hickman RO, Watkins SL. Safety and efficacy of erythropoietin in children with chronic renal failure. Pediatr Nephrol. 1999;13:143-7. [PMID: 10229004]
27. Cianciaruso B, Ravani P, Barrett BJ, Levin A; ITA-EPO-7 investigators. Italian randomized trial of hemoglobin maintenance to prevent or delay left ventricular hypertrophy in chronic kidney disease. J Nephrol. 2008;21:861-70. [PMID: 19034870]
28. Conlon PJ, Kovalik E, Schumm D, Minda S, Schwab SJ. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure. Ren Fail. 2000;22:435-44. [PMID: 10901181] (Pubitemid 30441639)
29. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-84. [PMID: 17108342]
30. Foley RN, Parfrey PS, Morgan J, Barré PE, Campbell P, Cartier P, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000;58:1325-35. [PMID: 10972697]
31. Furuland H, Linde T, Ahlmén J, Christensson A, Strömbom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant. 2003;18:353-61. [PMID: 12543892] (Pubitemid 36181688)
32. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004;66:753-60. [PMID: 15253730] (Pubitemid 38982019)
33. Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, Carlisle E, et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis. 2005;46:799-811. [PMID: 16253719]
34. Macdougall IC, Temple RM, Kwan JT. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial. Nephrol Dial Transplant. 2007;22:784-93. [PMID: 16968726]
35. Ritz E, Laville M, Bilous RW, O'Donoghue D, Scherhag A, Burger U, et al; Anemia Correction in Diabetes Study Investigators. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis. 2007;49:194-207. [PMID: 17261422]
36. Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Hawley C, et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol. 2004;15:148-56. [PMID: 14694167]
37. Rossert J, Levin A, Roger SD, Hörl WH, Fouqueray B, Gassmann-Mayer C, et al. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis. 2006;47:738-50. [PMID: 16632012]
38. Moher D, Schulz KF, Altman D; CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285:1987-91. [PMID: 11308435]
39. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al; CONSORT GROUP (Consolidated Standards of Reporting Trials). The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134:663-94. [PMID: 11304107]
40. Pfeffer MA. Critical missing data on erythropoiesis-stimulating agents in CKD: first beat placebo [Editorial]. Am J Kidney Dis. 2008;51:366-9. [PMID: 18295051]
41. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data. Cochrane Database Syst Rev. 2009:CD007303. [PMID: 19588423]
42. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373:1532-42. [PMID: 19410717]
43. van der Meer P, Groenveld HF, Januzzi JL Jr, van Veldhuisen DJ. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart. 2009;95:1309-14. [PMID: 19168472]
44. McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, et al; RED-HF Committees and Investigators. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail. 2009;11:795-801. [PMID: 19633103]
45. Bode-Böger SM, Böger RH, Kuhn M, Radermacher J, Frölich JC. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int. 1996;50:1255-61. [PMID: 8887285]
46. Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D, Kaufman J. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. J Clin Epidemiol. 2004;57:1086-95. [PMID: 15528060]
47. Himmelfarb J, Szczech LA. Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: con. J Am Soc Nephrol. 2009;20:1441-3. [PMID: 19579287]
48. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis. 2004;44:866-76. [PMID: 15492953]
49. National Kidney Foundation. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target. New York: National Kidney Foundation; 2007. Accessed at www.kidney.org/professionals/KDOQI/guidelines-anemiaUP/index.htm on 23 February 2010.
50. McMahon L; Caring for Australians with Renal Impairment (CARI). The CARI guidelines. Biochemical and haematological targets. Haemoglobin. Nephrology (Carlton). 2008;13 Suppl 2:S44-56. [PMID: 18713123]